ライフサイエンスコーパス: cardiovascular event

1 ral complications, in-hospital major adverse cardiovascular event).

2 ertugliflozin vs. placebo] for major adverse cardiovascular events).

3 bserved in the primary outcome (composite of cardiovascular events).

4 nge, 54 to 81 years]) and 11.7% had an acute cardiovascular event.

5 wnership with a better outcome after a major cardiovascular event.

6 e correlated with lower 30-day major adverse cardiovascular event.

7 T2DM patients with a previous major adverse cardiovascular event.

8 fluenza, almost 12% of patients had an acute cardiovascular event.

9 ence in a composite outcome of major adverse cardiovascular events.

10 Results were similar for major adverse cardiovascular events.

11 poprotein (LDL) cholesterol results in fewer cardiovascular events.

12 ve stress that correlates with occurrence of cardiovascular events.

13 ients remain at high risk of developing late cardiovascular events.

14 ate with endothelial dysfunction and predict cardiovascular events.

15 ed in patients at low risk for major adverse cardiovascular events.

16 ior to placebo with respect to major adverse cardiovascular events.

17 s not been fully evaluated as a predictor of cardiovascular events.

18 and a higher risk of atherosclerosis-related cardiovascular events.

19 ere not associated with the risk of death or cardiovascular events.

20 gnificantly reduce the risk of major adverse cardiovascular events.

21 T dynamics during exercise and recovery with cardiovascular events.

22 kely to experience longer-term major adverse cardiovascular events.

23 poproteins (remnant cholesterol) can predict cardiovascular events.

24 mab would reduce the total burden of serious cardiovascular events.

25 oprotein(a) concentration is associated with cardiovascular events.

26 d counterparts regarding mortality and major cardiovascular events.

27 y is associated with increased risk of major cardiovascular events.

28 ater in men than women and are predictive of cardiovascular events.

29 needed to determine the effects of SNF472 on cardiovascular events.

30 l cardiac mechanics and an increased risk of cardiovascular events.

31 ibration for predicting 5-year major adverse cardiovascular events.

32 both primary ischemic stroke and subsequent cardiovascular events.

33 nce of high-risk coronary plaque and risk of cardiovascular events.

34 are at high risk for major adverse limb and cardiovascular events.

35 ntribution of plaque and systemic factors to cardiovascular events.

36 viduals from UK Biobank without a history of cardiovascular events.

37 ich failed to show significant reductions in cardiovascular events.

38 volume by T1 mapping and was associated with cardiovascular events.

39 ardiometabolic health and increases rates of cardiovascular events.

40 lide, with a 54% lower risk of major adverse cardiovascular events.

41 to evaluate the effect of statin therapy on cardiovascular events.

42 Incident CVD included nonfatal and fatal cardiovascular events.

43 as Mediterranean diet) and the incidence of cardiovascular events.

44 ction and impairment of cardiac function and cardiovascular events.

45 an important independent predictor of future cardiovascular events.

46 lure (HF) are at high risk for major adverse cardiovascular events.

47 sociated with an increased risk of recurrent cardiovascular events.

48 ) have increased risk on future cerebro- and cardiovascular events.

49 rsus Mediterranean diet) on the incidence of cardiovascular events.

50 RT was not associated with increased risk of cardiovascular events.

51 ischemia and also be a predictor of adverse cardiovascular events.

52 to assess the incidence rate of LVNC-related cardiovascular events.

53 he inpatient management of adults with acute cardiovascular events.

54 ngly associated with increased mortality and cardiovascular events.

55 sociated with an increased incidence of late cardiovascular events.

56 is affects postintervention adverse limb and cardiovascular events.

57 on between slopes and the risks of death and cardiovascular events.

58 dently associated with cardiac mechanics and cardiovascular events.

59 e 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00) for majo

60 sociated with a higher risk of major adverse cardiovascular event (23.2% versus 13.4%; OR, 3.38 [95%

61 n reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and

62 death (40.9% versus 54.5%) and major adverse cardiovascular events (47.6% versus 59.5%), but with a l

63 espect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiov

64 s were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarct

65 on between eGFR slopes and risks of death or cardiovascular events, accounting for multiple confounde

66 th early-stage breast cancer who experienced cardiovascular events after cancer diagnosis had increas

67 ed survival and greater freedom from adverse cardiovascular events after complete revascularization (

68 after exercise, suggesting a reduced risk of cardiovascular events after exertion.

69 -terminal pro-B-type natriuretic peptide and cardiovascular events after noncardiac surgery: a cohort

70 he association between LDL-C and longer-term cardiovascular events after PCIs.

71 rt study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard rati

72 olic and systolic indices, as well as future cardiovascular events (all P<0.05).

73 pharmacy supply >30 days) and major adverse cardiovascular events (all-cause death, myocardial infar

74 Myocardial infarction is a frequent cardiovascular event and a major cause for cardiomyocyte

75 nificant association between risk of a first cardiovascular event and any infection in the previous 3

76 e supports a strong link between the risk of cardiovascular events and all-cause mortality with PM(2.

77 CE, is associated with an increased risk for cardiovascular events and all-cause mortality.

78 levels, lipoprotein levels, and the risk of cardiovascular events and cancer.

79 as performed on 50 adult patients with acute cardiovascular events and cardiac arrest survivors, test

80 th, other cancers, and major adverse events (cardiovascular events and fractures).

81 c inflammation independently predicts future cardiovascular events and is associated with a 2-fold in

82 nular calcification (MAC) is associated with cardiovascular events and mitral valve dysfunction.

83 to investigate the effects of liraglutide on cardiovascular events and mortality in LEADER (Liragluti

84 ase, is associated with an increased risk of cardiovascular events and mortality.

85 ne disease associated with an increased risk cardiovascular events and mortality.

86 provides a simple, novel strategy to predict cardiovascular events and progression in PAD patients.

87 sease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conventional

88 ffects of yoga-based CR (Yoga-CaRe) on major cardiovascular events and self-rated health in a multice

89 ause they decrease the risk of major adverse cardiovascular events and slow progression of diabetic k

90 imed at reducing the risk of atherosclerotic cardiovascular events and their adverse prognostic conse

91 predict the risk of death or a major adverse cardiovascular event, and their differences (ie, the est

92 c plaques are destabilizing, predict adverse cardiovascular events, and are associated with increased

93 d 2842 controls matched by age, a history of cardiovascular events, and cancer type.

94 nt 5-year all-cause mortality, major adverse cardiovascular events, and initiation of kidney replacem

95 ucing SSB consumption on diabetes incidence, cardiovascular events, and mortality in Argentina during

96 substantial decrease in diabetes incidence, cardiovascular events, and mortality in Argentina.

97 ition, serious adverse events, major adverse cardiovascular events, and other adverse events.

98 ial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboemb

99 hronic kidney disease and/or atherosclerotic cardiovascular events, and the risk of death.

100 Cardiovascular events are among the leading cause of mor

101 indicate that these daily rhythms in adverse cardiovascular events are at least partially under the c

102 The risks of cardiovascular events are frequently underestimated and

103 echanisms through which NSAIDs cause adverse cardiovascular events are not entirely understood.

104 Cardiac dysfunction and cardiovascular events are prevalent among patients with

105 Arterial cardiovascular events are the leading cause of death in

106 id (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy i

107 lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than

108 The increased risk of cardiovascular events associated with aromatase inhibito

109 chronic conditions, to protect against acute cardiovascular events associated with influenza.

110 and lipid levels were effective in reducing cardiovascular events, blood pressure, low-density lipop

111 h PAD are at risk for not only major adverse cardiovascular events but also major adverse limb events

112 ow-dose aspirin (100 mg/d) does not decrease cardiovascular events but does increase surgical bleedin

113 bsolute risks of mortality and major adverse cardiovascular events, but also with a lower absolute ri

114 in patients with a low risk of major adverse cardiovascular events, but may be useful in patients wit

115 ffective strategies for reducing the risk of cardiovascular events, but multiple studies have reporte

116 .69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-index=0.65 [0.61-0.69] for PCI

117 ting 10-year deaths and 5-year major adverse cardiovascular events can help to identify individuals w

118 fety endpoint was freedom from major adverse cardiovascular events (cardiac death, myocardial infarct

119 ssociated with decreased risk of significant cardiovascular events compared to nonsurgical controls.

120 icipants in the minimal care group had major cardiovascular events compared with 202 (5.9%) of 3421 p

121 .6% in the intervention groups experienced a cardiovascular event, compared with 4.4% in the control

122 vascular disease and risk stratification for cardiovascular events constitute an important part of th

123 rly kidney function, and impact of long-term cardiovascular events (CVE) after liver transplantation

124 lysis, SAF is an independent risk factor for cardiovascular events (CVEs) and all-cause mortality (AC

125 ily history of atrial fibrillation (AF) with cardiovascular events (CVEs), major adverse cardiac even

126 ostic value of QT dynamics was evaluated for cardiovascular events (death or hospitalization) and all

127 Secondary outcomes included major adverse cardiovascular events (death, myocardial infarction, str

128 s complications, lower risk of major adverse cardiovascular events, death, new MI, and new onset hear

129 The risk of composite cardiovascular events decreased in the surgical group [h

130 to predict the 5-year risk of major adverse cardiovascular events (defined as a composite of all-cau

131 ough in-hospital mortality and major adverse cardiovascular events did not differ by race/ethnicity a

132 d an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.

133 luenza may contribute to the burden of acute cardiovascular events during annual influenza epidemics.

134 risk (>=1%) for perioperative major adverse cardiovascular events during the surgical hospital admis

135 e the influence of LDL-C on the incidence of cardiovascular events either following a coronary revasc

136 resulting in increased risk of major adverse cardiovascular events, especially after percutaneous cor

137 esterol (LDL-C) is associated with increased cardiovascular events, especially in high-risk populatio

138 ents of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction,

139 e was projected to avert 40-54 major adverse cardiovascular events for every 1000 patients treated fo

140 ase-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-y

141 Atherosclerosis progression predicts cardiovascular events; however, progression of multiterr

142 FA) has been associated with reduced risk of cardiovascular events; however, this has not been confir

143 progressively increasing risks of death and cardiovascular events; however, we found no increased ri

144 .39; for a slope 1 SD below the average) and cardiovascular events (HR, 1.19; 95% CI, 1.03 to 1.38).

145 n though the risk of clonal progression or a cardiovascular event in an individual patient with clona

146 ignificantly reduces the first major adverse cardiovascular event in patients with prior myocardial i

147 o an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls

148 mg/dL in terms of reducing the risk of major cardiovascular events in 2860 patients with ischemic str

149 Genetic risk scores were not associated with cardiovascular events in 357 882 unrelated individuals f

150 d remnant cholesterol (remnant-C) with major cardiovascular events in a cohort of older individuals a

151 entify individuals at risk for major adverse cardiovascular events in a community-based cohort.

152 associated with increased risks of death and cardiovascular events in a U-shaped fashion.

153 tive myocardial infarction and major adverse cardiovascular events in adults aged 75 years or older (

154 LAEDVI is a strong predictor of cardiovascular events in ambulatory patients with stable

155 n did not significantly reduce major adverse cardiovascular events in any voucher use likelihood grou

156 lcium (CAC) to predict risk of major adverse cardiovascular events in asymptomatic patients is accept

157 While elevated risk and incidence of cardiovascular events in breast cancer is well establish

158 tty acid formulation to reduce major adverse cardiovascular events in high-risk patients.

159 been shown to lead to a marked reduction in cardiovascular events in humans.

160 ociated with increased risk of major adverse cardiovascular events in individuals <55 years of age (h

161 agents vorapaxar and prasugrel for reducing cardiovascular events in patients at high cardiovascular

162 t as a strategy to reduce risk for recurrent cardiovascular events in patients who have had recent is

163 icagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary sy

164 OSA has not been shown to increase recurrent cardiovascular events in patients with acute coronary sy

165 and secondary prevention of atherosclerotic cardiovascular events in patients with CAD and DM.

166 apies aimed at further reducing the risks of cardiovascular events in patients with chronic - but not

167 -stimulating agents (ESAs) may contribute to cardiovascular events in patients with CKD and anemia.

168 hibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chr

169 ssociations between LGE presence and adverse cardiovascular events in patients with dilated cardiomyo

170 e consistently shown safety and reduction in cardiovascular events in patients with established CVD.

171 ss and sleeve gastrectomy) and major adverse cardiovascular events in patients with previous myocardi

172 es Mellitus), PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

173 ab significantly reduced the total number of cardiovascular events in patients with prior MI and evid

174 ory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial

175 and have also been shown to reduce recurrent cardiovascular events in patients with stable coronary d

176 is associated with increased risk of future cardiovascular events in patients with subclinical, nono

177 RNC may translate into a reduction in future cardiovascular events in psoriasis.

178 wledge gap exists regarding their effects on cardiovascular events in real-world populations.

179 tory effects and a reduced risk of recurrent cardiovascular events in stable patients with previous m

180 s common but not associated with survival or cardiovascular events in this study.

181 ney disease on abnormal cardiac function and cardiovascular events in those without overt coronary ar

182 age-adjusted incidence rate of major adverse cardiovascular events, in contrast to 13% in individuals

183 Longer-term (up to 4 years) major adverse cardiovascular events, including all-cause death, myocar

184 effect of canakinumab on the total number of cardiovascular events, including recurrent events collec

185 the use of aspirin for primary prevention of cardiovascular events is a suitable and laudable approac

186 sed medication persistence and major adverse cardiovascular events is unknown.

187 EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of on

188 HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential tre

189 ll-cause death and major adverse cardiac and cardiovascular events (MACCE) as outcomes of interest.

190 once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular de

191 s were: 1) first occurrence of major adverse cardiovascular events (MACE) (composite of all-cause mor

192 The majority of stent-related major adverse cardiovascular events (MACE) after percutaneous coronary

193 luence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported w

194 ), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OU

195 en shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone

196 se (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those without

197 primary composite endpoint of major adverse cardiovascular events (MACE) comprised coronary heart di

198 al stress is a risk factor for major adverse cardiovascular events (MACE) in individuals with coronar

199 ease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the Diabetes Control and

200 Predefined end points were major adverse cardiovascular events (MACE) within 12 months.

201 ated with a lower incidence of major adverse cardiovascular events (MACE), all-cause mortality, and r

202 cts of their unbalanced use on major adverse cardiovascular events (MACE), defined as cardiovascular

203 mary outcome was the report of major adverse cardiovascular events (MACE), defined as incident myocar

204 followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular

205 ess MBF and MPR with death and major adverse cardiovascular events (MACE), including myocardial infar

206 Major adverse cardiovascular events (MACE), which included death, stro

207 required to see a reduction in major adverse cardiovascular events (MACE).

208 (Hounsfield units) may predict major adverse cardiovascular events (MACE).

209 ty [AmygA]) and higher risk of major adverse cardiovascular events (MACE).

210 LDL-C independently predicted major adverse cardiovascular events (MACE).

211 ated with a lower incidence of major adverse cardiovascular events (MACE, adjusted HR 0.80, 95% CI 0.

212 Rates of 5-year major adverse cardiovascular events (MACE; a composite of cardiac deat

213 ition risk and all-cause mortality and major cardiovascular events (MACEs) (cardiovascular mortality,

214 olic blood pressure (SBP) with major adverse cardiovascular events (MACEs) and major adverse limb eve

215 lipid profile and searched for major adverse cardiovascular events (MACEs) in the high-risk primary p

216 Major adverse cardiovascular events (MACEs) were analyzed.

217 y endpoints included composite major adverse cardiovascular events (MACEs), all-cause mortality, and

218 ed the rates of the composite of all serious cardiovascular events (MI, stroke, coronary revasculariz

219 Cardiovascular events, mortality, subjective well-being,

220 mary composite outcome of mortality or major cardiovascular event [multivariate HR (mvHR): 0.88; 95%

221 y outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary r

222 y and the secondary outcome of major adverse cardiovascular events (myocardial infarction, heart fail

223 lar disease (CVD) and incident major adverse cardiovascular events (myocardial infarction, stroke, or

224 Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or

225 ary endpoint was the development of specific cardiovascular events - myocardial infarction (MI), and

226 omposite events [deaths (n = 8,662) or major cardiovascular events (n = 5,979)].

227 utcome was a composite of mortality or major cardiovascular event [nonfatal myocardial infarction (MI

228 ome for this review was a composite of fatal cardiovascular events, nonfatal myocardial infarction, a

229 ing a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the

230 of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (1

231 3.7 years of follow-up, 3,417 total serious cardiovascular events occurred in 2,003 individuals amon

232 03], P<0.001), and in-hospital major adverse cardiovascular events (odds ratio, 1.8 [95% CI, 1.42-2.1

233 d to assess noninferiority for major adverse cardiovascular events of the BioFreedom stent compared w

234 rategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparis

235 ative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a med

236 intervention and usual care groups included cardiovascular events or hospitalizations (4 [2.0%] vs 7

237 No trials were powered to assess cardiovascular events or prostate cancer, and trials oft

238 tima-medial thickness alone did not predict (cardiovascular) event or improve risk assessment beyond

239 me until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.

240 e) and pathophysiology (eg, onset of adverse cardiovascular events) oscillate during the 24-hour day.

241 The hazard ratios for composite cardiovascular events outcome in propensity score-matche

242 The primary composite major adverse cardiovascular events outcome was time to first occurren

243 o important reasons: the continuing risks of cardiovascular events over the longer term and the diver

244 ll led to a steady increase in major adverse cardiovascular events over time.

245 entions were associated with a lower risk of cardiovascular events (pooled relative risk, 0.80 [95% C

246 hat trained immunity underlies the increased cardiovascular event rate in PHEO patients.

247 The adjudicated cardiovascular event rate was 2.7% per year.

248 ure success rate was 61.4% and major adverse cardiovascular event rate was 4.2%.

249 All cause death, stroke, and cardiovascular event rates were similar between the grou

250 rgeting of IL-1beta can significantly reduce cardiovascular event rates without lipid or blood pressu

251 independently influenced the risk of adverse cardiovascular events, regardless of the definition of h

252 mplexity ACHD had a higher burden of adverse cardiovascular events relative to the general population

253 baseline cardiovascular risk and subsequent cardiovascular events requires further investigation.

254 The effect of OSA on recurrent cardiovascular event risk was evaluated for each phenoty

255 The primary end point was cardiovascular events; secondary end points were all-cau

256 tidase 4 inhibitors have variable effects on cardiovascular events, sodium glucose cotransporter 2 in

257 hat begin with lifestyle choices and lead to cardiovascular events span multiple organ systems, inclu

258 on as well as ischemic stroke, major adverse cardiovascular events, splanchnic vein thrombosis, and b

259 mary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack

260 Risk of a first cardiovascular event strongly associated with a recent i

261 fic-related noise and the incidence of major cardiovascular events such as acute myocardial infarctio

262 iovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke.

263 and COVID-19 infection and the risk of acute cardiovascular events, summarize the data to date on the

264 sk of developing MI, stroke, and any type of cardiovascular event than gastric bypass patients.

265 ssures (BP) are more predictive of long-term cardiovascular events than clinic BP.

266 ill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participant

267 such, they are more prone to atherosclerotic cardiovascular events than patients without DM, both bef

268 sulted in lower risks of CKD progression and cardiovascular events than placebo.

269 pass was associated with a lower risk of all cardiovascular events than sleeve gastrectomy.

270 an be a potential modifiable risk factor for cardiovascular events, that is, surgical technique, type

271 associated with an increased risk of adverse cardiovascular events, the accurate incidence of cardiov

272 is often limited by the unpredictability of cardiovascular events, the intermittent nature of ambula

273 DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarct

274 1, with stratification according to previous cardiovascular events) to continue allopurinol (at the o

275 anoma skin cancer, other malignancies, major cardiovascular events, venous thromboembolism, and morta

276 the patients, the incidence of major adverse cardiovascular events was 2.9% in the relugolix group an

277 int of the 30-day freedom from major adverse cardiovascular events was 92.2%; the lower bound of the

278 year cumulative probability of major adverse cardiovascular events was lower in patients undergoing m

279 Overall, no risk reduction on major adverse cardiovascular events was observed (HR: 0.91 [95% CI 0.8

280 s with chronic coronary disease, the risk of cardiovascular events was significantly lower among thos

281 y indexes of neutrophilia with major adverse cardiovascular events was studied in a cohort of patient

282 The primary end point, major adverse cardiovascular events, was defined as the composite of c

283 e adjusted subdistribution hazard ratios for cardiovascular events were 1.17 (95% confidence interval

284 rpes zoster infection, malignancy, and major cardiovascular events were 2.81 per 100 person-years, 2.

285 After a median 3.2 years, the rates of cardiovascular events were 55.2/1,000 person-years for t

286 Acute cardiovascular events were ascertained using discharge c

287 liraglutide versus placebo on major adverse cardiovascular events were consistent in patients with (

288 Cardiovascular events were higher after initiation of IC

289 Acute cardiovascular events were identified by ICD discharge c

290 Longer-term major adverse cardiovascular events were lower in the CAC-absent (2.4%

291 The largest reductions in diabetes and cardiovascular events were observed in the youngest age

292 iations between eGFR, cardiac mechanics, and cardiovascular events were partly mediated via CFR.

293 ociated with greatest risk for major adverse cardiovascular events, while prior peripheral revascular

294 symptoms, and individualizing their risk of cardiovascular events with a special consideration for n

295 exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes

296 he absolute risk reduction for major adverse cardiovascular events with alirocumab was numerically gr

297 This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Interventio

298 REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention

299 a-3 fatty acids hold the potential to reduce cardiovascular events with limited adverse effects in th

300 nakinumab reduced the rates of total serious cardiovascular events, with rates per 100 person-years i